Global Trac Solutions, Inc.'s (OTC Pink: PSYC) Psychedelic Spotlight is now the undisputed leader in providing the most accurate and timely information about an industry that could help revolutionize medical treatment- medicinal psychedelics. And users of its website learned quickly of a California Senate bill considered the most progressive yet to advance the promise inherent to the psychedelics treatment sector.
In fact, that bill can be a ground-breaking precedent for the industry, with many believing it could pave the path toward decriminalization of psychedelics nationwide. And with medicinal psychedelics showing a tremendous ability to treat patient conditions as an alternative to chemically-filled prescription drugs, the winners will be patients.
Providing the most up-to-date coverage on the advancing legislation, Psychedelic Spotlight sat with a sponsor of the bill, CA Senator Scott Wiener (D-San Francisco), to discuss its intention to decriminalize the possession and sharing of certain hallucinogenic/psychedelic substances within the state. If you think it's a far-reaching quest, remember, so was CBD just five years ago.
And, know this. The bill cleared its first major hurdle in June when it was passed in a 21-16 vote by the state Senate resulting in it moving to the state Assembly for review. That puts the legislation on a trajectory toward approval. And that could be excellent news for PSYC stock and for its flagship website, Psychedelic Spotlight.
Breaking Through The Wall
Indeed, many don't expect the bill to pass the first time through. However, CBD-based therapeutics didn't either. And now they are mainstream. Still, while challenges to the measure exist, signs indicate that the opposition is weakening as data shows the compelling benefits the drugs can bring to patients suffering many medical conditions. Thus, while passage may not happen in 2021, the bill clearing the state Senate is an encouraging sign of the positive momentum that continues to build behind psychedelics throughout society.
For PSYC, which decided to reposition its mission to exploit the market opportunities in the emerging sector of medicinal psychedelics, that's good news. Moreover, as one of the few publicly traded companies providing direct exposure into the industry, its shares trading at $0.014 may present a compelling investment opportunity. In fact, like the reputable CBD and cannabis stocks a decade ago, PSYC could deliver exponential returns. Most importantly, this company is here to stay.
In fact, PSYC could be the best-positioned company in the sector to deliver returns similar to those of the early cannabis stocks. However, unlike many of those, PSYC owns an industry-leading brand and website, has an impressive capital structure, and is respected by users, scholars, politicians, and medical researchers. And that makes this investment consideration compelling.
Even better, PSYC could benefit from a landmark catalyst from SB 519 that has already put the psychedelic movement into the spotlight. And not only in California, but researchers and proponents across the nation are also paying attention to the bill's journey. Why?
Because there is a mental health crisis in this country. And California is the first to start the conversation on the benefits of medicinal psychedelics, with CA Senator Scott Wiener addressing the problems head-on. In fact, in an exclusive interview with Psychedelic Spotlight, he acknowledged that psychedelics can significantly benefit people struggling with addiction and mental health challenges.
Moreover, he noted that while psychedelic treatment may not be a global solution, it may provide safer treatment than current care standards. It could also help replace medications whose side effects are worse than the initial treatment they are prescribed to help. Thus, starting the conversation now can lead to alternative solutions sooner rather than later.
And Psychedelic Spotlight has become the go-to source of relevant, accurate, and timely updates about the sector.
Video Link: https://www.youtube.com/embed/UOHhkOGrW8g
The Leading Industry Website
In fact, PSYC's Psychedelic Spotlight does more than publish compelling and timely information for readers, investors, and consumers about the sector. As noted, it's also one of the few direct investment opportunities into an industry bringing meaningful change to how patients get treated for many medical conditions. And its surging user base is a testament that patients and researchers are paying attention to its news.
In June, PSYC reported that the website reached its highest monthly user totals ever, coming in over 25% higher than the previous month. And that growth followed a period of equally impressive growth during the month prior. And as interest in the sector continues to increase, Psychedelic Spotlight is expected to grow along with it. Deservedly so.
In fact, there are few, if any, news sources that offer the same comprehensive coverage as Psychedelic Spotlight. That's important to the value proposition of PSYC stock.
Remember, too, the medicinal function isn't a byproduct of recreational use during the 1960s. It's a researched and validated means to provide a competitively beneficial alternative to prescription drugs that often have severe side effects. Moreover, it has the potential to get into the hands of patients soon, with industry experts thinking their use can follow the same regulatory path as CBD, which became a multi-billion-dollar treatment alternative after less than a decade in the markets. There are reasons to be optimistic.
Studies indicate that medicinal psychedelics have enormous potential to treat mental and physical conditions, with data suggesting benefits for chronic pain, depression, and PTSD. And the excellent news for those wanting to learn more is that Psychedelic Spotlight publishes a comprehensive variety of up-to-date information in editorial, video, culture pieces, and interview formats.
In fact, Psychedelic Spotlight is referred to as the most all-inclusive resource for investors, clients, and patients to seek out news in the industry. Moreover, it's one of the only platforms that regularly allows experts in the field to contribute information that benefits readers, researchers, and providers alike. Indeed, the website can be instrumental in helping to usher in the movement.
Changing The Dialogue For Psychedelics Treatment
Here's the critical thing to know. Therapeutic advancements in the psychedelics sector are evidence-based and supported by esteemed professionals. Better still, ongoing trials and studies are adding volumes of data supporting the promise of these therapies as a viable and effective alternative to standard-of-care medicines. And with Psychedelic Spotlight usually the first to publish updates regarding these studies, keeping track of advancements isn't hard to find.
Even better, Psychedelic Spotlight is helping to erase the previously taboo nature of the psychedelics industry by offering its readers facts instead of conjecture. Moreover, it is helping to break through a decades-long coverup of psychedelics' potential as a treatment alternative and provides a welcoming forum for public opinion. And from an investor's perspective, by offering up-to-the-minute news and events from the sector, it has extraordinary value as well.
In fact, it allows readers and investors to compare the pace of acceptance to that of CBD, which has quickly become an immensely popular alternative to opioids based on compelling results in treating patients with anxiety, depression, chronic pain, and other conditions. And its mainstream acceptance has happened quickly, leading many experts to believe that the psychedelics sector can mirror that growth within ten years.
Thus, a value proposition is born. And with PSYC shares trading at pennies per share, investment consideration is more than attractive; it's compelling.
Partnerships Add More Value
In fact, PSYC investors are buying into a company in hyper-growth mode. Already, PSYC has formed partnerships with established researchers to strengthen its credibility and stay up to date on sector developments. Better still, its collaboration with The Conscious Fund and 15% investment stake in PsycheDEV Inc. are already creating shareholder value. And as its partners continue to expand their reach into the sector, expect PSYC to benefit as well.
The investments also offer diversity. Like its own website, The Conscious Fund provides a platform for "all things" psychedelic with an intense focus on research. There, the combined mission highlights the benefits of alternative treatments utilizing plant-based therapeutics derived from ketamine, mushrooms, and MDMA. Its primary message intends to erase the stigma associated with these drugs and highlight the benefits they offer for numerous patient health issues.
Its 15% ownership in PsycheDev Inc. offers more value. PsycheDev's mission is unique, offering guided trips programs and tools to facilitate growth by helping people better understand themselves and others. It's an innovative approach to treatment that creates an experience that develops a patient's psyche from its everyday ways to a deeper inner world. Its goal is to help clients achieve an experience that expands the mind by guiding them through intention setting, meditation, learning, contemplation, and questioning. Innovative for sure. And demand for its services is rising.
A Mushrooming Industry Worth Nearly $7 Billion By 2027
And that demand makes sense, especially with the medicinal psychedelics industry projected to hit a $6.85 billion valuation within 6 years. Even better, expectations are for the growth curve to steepen as more data is available showing benefits to treat a more extensive range of medical conditions.
In fact, industry growth is accelerating as researchers continue to support that the use of medicinal psychedelics can effectively treat mental disorders, anxiety, and chronic pain. Already, trials have shown that psilocybin treatments can significantly benefit patients with depression and sidestep the adverse side effects of heavily prescribed medicines. Better still, there is promising evidence that psychedelic therapies can allow patients to live their lives without any of the physical side effects associated with traditional pharmaceutical treatments, especially those that can have side effects worse than the original condition.
Undoubtedly, there is a need for better treatment. Just ask people addicted to pharmaceutical drugs as an unintended side effect from treating a medical condition. Moreover, a new generation is ushering in an entirely new set of values, paying attention to eco-friendly brands, products, and all-natural food and treatment choices. CBD is an example of the latter.
Best of all, beyond the benefits inherent to Psychedelic Spotlight, the billions of dollars up for grabs in this emerging industry can be a source of fuel for PSYC as well. Better still, it's not a matter of if; it's now a matter of when this industry will mushroom into a mainstream treatment market. According to publications on Psychedelic Spotlight, it's happening faster than anyone would have ever imagined.
And that's excellent news for both Psychedelic Spotlight and Global Trac Solutuions, Inc.
Disclaimers: Hawk Point Media Group, LLC. (Hawk Point Media) is responsible for the production and distribution of this content. Hawk Point Media is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Hawk Point Media is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Hawk Point Media be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Hawk Point Media, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found by clicking HERE.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Media Contact
Company Name:Hawk Point Media
Contact Person: KL Feigeles
Email:info@hawkpointmedia.com
Phone: 3057806988
City: Miami Beach
State: Florida
Country: United States
Website: https://www.hawkpointmedia.com
